Working Groups

Latest News

Register now

ISAC is proud to support the upcoming 4th International Conference on Polymyxins.

Read More
Travel Grants to attend ...

Apply for Young Investigator &Eastern Europe Travel Grants for Istanbul.

Read More

Membership

Current Officers

Chair

Kordo Saaed

H Wertheim

Vice-Chair

Heiman Wertheim

Secretary

Peter Laszlo Kanizsai

Treasurer

Eric Gluck

All Members

Tomefa Asempa (USA)
Albertus Beishuizen (the Netherlands)
Mike Broyles (USA)
Ricard Ferrer (Spain)
Gaëtan Gavazzi (France)
Eric Howard Gluck (USA)
Juan González del Castillo (Spain)
Jens Ulrik Stæhr Jensen (Denmark)
Andrea Kwa (Singapore)
Stephen Kidd (UK)
Adi Klein (Israel)
Charles-Edouard Luyt (France)
Syafinaz Amin Nordin (Malaysia)
Michael Oppert (Germany)
Gargi Patel (USA)
Mario Plebani (Italy)
Steve Poole (UK)
Isatou Sarr (UK)
Philipp Schütz (Switzerland)
Sergey Shlyapnikov (Russian Federation)
Giulio Toccafondi (Italy)
Jennifer Townsend (USA)
Tobias Welte (Germany)
Yu Choo Yee (Malaysia)

How to Join

ISAC Working Groups are open to new members with a strong interest and relevant experience in the given field. To join an ISAC Working Group, please contact Fee Johnstone, ISAC Executive Officer secretariat@isac.world with your name and a brief C.V. We welcome new members!

Aims and Objectives

Given the amount of research and investment in the field of novel diagnostics and biomarkers, it is predicted that provision of medicine in the future will be transformed. The main aims of novel diagnostics and biomarkers are not only to recognise infection and/or sepsis, but also to assist in triaging patients with regards to avoiding admission, ward admission, intensive care admission and even prognosis and predicting outcome.

 

Another aspect of novel diagnostics and biomarkers is to improve antibiotic stewardship in clinical settings. Therefore, this working group aims to: 

  • Organise educational meetings and provide educational material on the application of novel diagnostics and biomarkers in clinical practice e.g. antibiotic stewardship and/or triaging.
  • Promote a “network” to collect data from those centres that use novel diagnostics and/or biomarkers and audits of good practice with regards to novel diagnostics and biomarkers.
  • Develop practice guidelines or recommendations for a correct approach in applying these novel technologies and biomarkers in clinical practice.

We hope that the group’s work will result in a closer collaboration among international experts who can bridge the gap between studies, clinical applications and patients’ needs, thereby improving not only antibiotic stewardship and better quality of patient care, but also in reducing the cost to healthcare systems across the world.

Webinars

 Rapid diagnostics and strain typing in the era of antimicrobial resistance

The aim is to learn from current experiences across the globe on how rapid diagnosis impacts on curbing antimicrobial resistance (AMR).

 -----------------------------------------------------------

Rapid diagnostics & biomarkers at the heart of patient management

In this webinar, ISAC’s Rapid Diagnostics & Biomarkers Working Group provided a number of short presentations on how rapid and novel diagnostics and technologies and their application can impact clinical practice and the provision of microbiology, infectious disease, antimicrobial stewardship and infection control services.

 

Future / Ongoing Activities

Our ideas for the coming years are to organise coordinated (reviews or audits or quality improvement projects or even video lectures) related to biomarker incorporation to clinical practice for example in any of the following areas:

  • How to make sure point of care tests are complementary to medical microbiology and part of their overall diagnostic package. This can be challenging to achieve; however, it can be done through coordination and also registration for surveillance among the working group.
  • When to use biomarker testing versus targeted testing. (Writing reviews) 
  • How does lateral flow assays impact on what we do clinically? (Writing reviews)
  • For resistance markers, do we still need to know the bug? (Writing review)

Publications

How are rapid diagnostic tests for infectious diseases used in clinical practice: a global survey by the International Society of Antimicrobial Chemotherapy (ISAC)
Poole, S, Townsend J, Wertheim et al on behalf of the ISAC Rapid Diagnostic and Biomarkers Working Group
Eur J Clin Microbiol Infect Dis. 2020

Hot topics on procalcitonin use in clinical practice, can it help antibiotic stewardship?
Saeed K, del Castillo JG, Backous C et al.
Int J Antimicrob Agents. 2019;54:686-696.

 

Last updated: May 13th-2024